புற்றுநோய் அட்லஸ் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from புற்றுநோய் அட்லஸ். Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In புற்றுநோய் அட்லஸ் Today - Breaking & Trending Today

Verastem Oncology Initiates Phase 2 Registration-Directed Trial of VS-6766 and Defactinib in Previously Treated KRAS Mutant Non-Small Cell Lung Cancer


Share:
Phase 2 Adaptive Trial Design to Evaluate VS-6766 Alone and in Combination with Defactinib With a Focus on KRAS-G12V Mutations
Trial Designed to Address Significant Unmet Medical Need in These Treatment-Resistant Tumors
Verastem Oncology to Seek FDA Accelerated Approval, Pending Trial Outcome
Verastem, Inc. (NASDAQ:VSTM) (also known as Verastem Oncology), a biopharmaceutical company committed to advancing new medicines for patients battling cancer, today announced the initiation of a Phase 2 registration-directed clinical trial of VS-6766, its RAF/MEK inhibitor, alone and in combination with defactinib, its FAK inhibitor, in patients with KRAS mutant non-small cell lung cancer (NSCLC).
Currently available options for patients with KRAS mutant NSCLC are associated with minimal efficacy, as well as resistance and toxicity issues. Our study will further elucidate the impact of VS-6766, alone or in combination with defactinib, in overcoming these challenge ....

United States , Brian Stuglik , Silvia Novello , D Ross Camidge , Pancancer Atlas , Chugai Pharmaceutical Co Ltd , Department Of Clinical , National Institute Of Health , Mayo Foundation For Medical Education , Drug Development Summit , University Of Colorado Cancer Center , Sciences Of The University Turin , Verastem Inc , Exchange Commission , Verastem Oncology Press , Raf And Mek Program , University Of Colorado School Medicine , American Cancer Society , Trial Design , Defactinib With , Address Significant Unmet Medical Need , These Treatment Resistant Tumors , Pending Trial , Verastem Oncology , Chief Executive Officer , Thoracic Oncology ,